Additional file 1 of An epithelial gene signature of trans-IL-6 signaling defines a subgroup of type 2-low asthma

Additional file 1: Table S1. Different experimental conditions of stimulation or treatment with IL-6, sIL-6Rα, Olamkicept and Tocilizumab. Table S2.Gene set enrichment analysis of the 4th quartile top 5% IL-6+sIL-6Rα induced genes (core enrichment genes). Table S3.Quantitative measurement of western-blot band density relatively compared to IL-6. Table S4. Teer Measurement after normalization, compared to control condition. Table S5. Area under the curve of real-time cell impedance measurements using xCELLigence system after 24 hours of stimulation. Table S6. Differentially expressed Genes by IL-6 vs. control.Table S7. Differentially expressed Genes by IL-6+sIL-6Rα vs. control. Table S8. Functional enrichments in genes significantly upregulated by IL-6/IL-6Rα in Biological Process (Gene Ontology). Table S9. IL-6/IL6-Rα Gene signature expression in response to Olamkicipt and Tocilizumab. Table S10. Description of the Study population. Table S11. GSEA results summary in current Asthma phenotype in bronchial biopsies cohort. Table S12. GSEA results summary in current Asthma phenotype in nasal brush cohort.附加文件1：表S1：白细胞介素-6（Interleukin-6, IL-6）、可溶性白细胞介素-6受体α（soluble Interleukin-6 receptor α, sIL-6Rα）、奥拉奇塞普（Olamkicept）与托珠单抗（Tocilizumab）的不同刺激或处理实验条件。表S2：第4四分位数中排名前5%的IL-6+sIL-6Rα诱导基因（核心富集基因）的基因集富集分析（Gene Set Enrichment Analysis, GSEA）结果。表S3：以IL-6为参照的蛋白质免疫印迹（Western-blot）条带密度相对定量检测结果。表S4：经归一化处理后的跨上皮电阻（TEER）测量结果，与对照组进行比较。表S5：采用xCELLigence系统对细胞进行24小时刺激后，实时细胞阻抗检测值的曲线下面积结果。表S6：IL-6处理组与对照组的差异表达基因分析结果。表S7：IL-6+sIL-6Rα处理组与对照组的差异表达基因分析结果。表S8：IL-6/IL-6Rα显著上调基因在生物过程（基因本体, GO）中的功能富集分析结果。表S9：奥拉奇塞普与托珠单抗处理后，IL-6/IL-6Rα基因特征的表达水平。表S10：研究人群的基本信息描述。表S11：支气管活检队列中当前哮喘表型的基因集富集分析结果汇总。表S12：鼻腔刷检队列中当前哮喘表型的基因集富集分析结果汇总。